Moteur de recherche d’entreprises européennes
Financement de l’UE (8 384 036 €) : La pandémie intérieure : s’attaquer à la vulnérabilité cérébrale chez les COVID19 à haute résolution : NEUROCOV Hor28/07/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
La pandémie intérieure : s’attaquer à la vulnérabilité cérébrale chez les COVID19 à haute résolution : NEUROCOV
The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients’ collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.
| Azienda Socio-Sanitaria Territoriale Fatebenefratelli Sacco | 0,00 € |
| BEN-Gurion University OF THE Negev | 197 635 € |
| Deutsches Zentrum FUR Neurodegenerative Erkrankungen e. V. | 1 840 030 € |
| Eurice European Research AND Project Office GmbH | 597 812 € |
| Fondazione Human Technopole | 3 234 940 € |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit UND Umwelt GmbH | 277 000 € |
| Helsingin Yliopisto | 359 840 € |
| Humanitas Mirasole S.p.A. | 0,00 € |
| Katholieke Universiteit Leuven | 199 218 € |
| Stichting Amsterdam UMC | 536 917 € |
| Umea Universitet | 180 362 € |
| Universita Degli Studi Di Milano | 960 283 € |
https://cordis.europa.eu/project/id/101057775
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.